Keep up the good work. Missed you more than I can explain. Am so depressed on this board from all the venom. Nonresident, Dude how bad is your portfolio, Tim seriously needs a restraining order from the likes of you. I wouldn't wanna be him.
CRUK's new forecast that incidence of cancer in the UK will rise from 1 in 3 to as high as 1 in 2 is a sobering thought, and one which further underlines the importance of Sareum's cancer-specific programmes in the UK and China.
Nonresident. Yes, Sareum nearly went under. But it didn't. Lots of companies were less fortunate during the early days of the financial crisis. SAR changed strategy and focused on drug discovery rather than providing services to large pharmas who were also cutting back on external spending.
As for Dr Harpers record. Drug discovery is high risk. Many companies go bust before doing their first licencing deal. But some make it to the first deal and beyond and that can be very rewarding to all involved.
Personally, I'm prepared to wait and see what happens. True, no deal - yet. But the further the three main programmes progress the more any potential deal will be worth. And until something goes wrong on the science front (which it hasn't yet) I can't see any reason to change my approach.
dr tapoczay was responsible for millenium _( read sentinel yeah they did a deal staff worked there ) and at soci.org you can read Dr Tapolczay has an international reputation in pharmaceutical chemical development, as well as an outstanding academic track record with a considerable .. .he should be invited to join the board - he presented in 2007
the current board as Arb ( posts recommended) has pointed out have form in financial wizardry - bust the company once - and look up dt tim sold out at 2.5p after pump and sell stories - he and Hybridan a f..... disgrace the chairman at ABH did the same financial wizardry - it went bust sell or ride out moronic - so the choice is not sell or ride out it is director changes
The negative sentiment is understandable given the time scales involved, plus some of the bullish comments by the Drs back in 2013 were perhaps too hasty, but that's understandable as they're scientists, not PR people. The recent newsflow is however quite encouraging -- particularly with regards to CHK1 -- if one takes a long-term (i.e. 1+ year) view. e.g. the increased role of BACIT, securing of patents in key locations, and synthesis of drugs in multi-gram quantities. Taken together it seems Sareum may soon be poised to move from pre-clinical to clinical trials.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.